

FORM PTO-1390 (Modified) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE (REV. 12-2004)		ATTORNEY'S DOCKET NUMBER PP022717.0004
TRANSMITTAL LETTER TO THE UNITED STATES • DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) Unassigned 10/593005
INTERNATIONAL APPLICATION NO. PCT/IB2005/000987	INTERNATIONAL FILING DATE 17 March 2005	PRIORITY DATE CLAIMED 17 March 2004

TITLE OF INVENTION
ANALYSIS OF SACCHARIDE VACCINES WITHOUT INTERFERENCE

APPLICANT(S) FOR DO/EO/US
Angela BARDOTTI, Daniela PROIETTI and Stefano RICCI


Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

- 1. ☒ This is a **FIRST** submission of items concerning a submission under 35 U.S.C. 371.
- 2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a submission under 35 U.S.C. 371.
- 3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
- 4. ☐ The US has been elected (Article 31).
- 5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
- 6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
- 7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
- 8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
- 9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
- 10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
- 11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
- 12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 23 below concern document(s) or information included:

- 13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
- 14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
- 15. ☒ A **FIRST** preliminary amendment.
- 16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
- 17. ☐ A substitute specification.
- 18. ☐ A power of attorney and/or change of address letter.
- 19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.
- 20. ☒ A second copy of the published International Application under 35 U.S.C. 154(d)(4).
- 21. ☐ A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).
- 22. ☒ Express Mail Label No. **EL987062178US**
- 23. ☒ Other items or information:
copy of unsigned Declaration for Patent Application

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER	
10/593005 Unassigned		PCT/IB2005/000987		PP022717.0004	
24. The following fees are submitted:				Applicant use	Office use
<input checked="" type="checkbox"/> a) Basic national fee \$300.00				\$ 300.00	
<input checked="" type="checkbox"/> b) Examination fee \$200.00				\$ 200.00	
<input checked="" type="checkbox"/> c) Search fee \$500.00				\$ 500.00	
TOTAL OF ABOVE CALCULATIONS = \$1000.00				\$ 1,000.00	
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole)	RATE		
29 - 100 =	-71 /50 =	-1	x	\$ 0.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 130.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	21 - 20 =	1	x \$50.00	\$ 50.00	
Independent claims	5 - 3 =	2	x \$200.00	\$ 400.00	
MULTIPLE DEPENDENT CLAIMS (if applicable) <input checked="" type="checkbox"/> + \$360.00				\$ 360.00	
TOTAL OF ABOVE CALCULATIONS =				\$ 1,940.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$ 0.00	
SUBTOTAL =				\$ 1,940.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$ 0.00	
TOTAL NATIONAL FEE =				\$ 1,940.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +				\$ 0.00	
TOTAL FEES ENCLOSED =				\$ 1,940.00	
Amount to be refunded:					\$
Amount to be charged:					\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>1,940.00</u> to cover the above fees is enclosed.					
b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is					
c. <input checked="" type="checkbox"/> The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>03-1664</u> . A duplicate copy of this sheet is enclosed.					
d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.					
SEND ALL CORRESPONDENCE TO:					
Novartis Vaccines and Diagnostics Inc			SIGNATURE		
Corporate Intellectual Property R338			Helen Lee		
P.O. Box 8097			NAME		
Emeryville, California 94662-8097			39,270		
US			REGISTRATION NUMBER		
Customer Number 27476					

PATENT
PP022717.0004

IAP16 Rec'd PCT/PTO 14 SEP 2006

10/593005

**PATENT COOPERATION TREATY
IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)**

International Application No.
PCT/IB2005/000987

International Filing Date
17 March 2005

Priority Date Claimed
17 March 2004

Title of Invention
ANALYSIS OF SACCHARIDE VACCINES WITHOUT INTERFERENCE

Applicants for DO/EO/US:
Angela BARDOTTI, Daniela PROIETTI and Stefano RICCI

CERTIFICATE OF MAILING BY EXPRESS MAIL

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Express Mail Mailing Label No.: EL987062178US

Date of Deposit: 15 September 2006

I hereby certify that the attached Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Filing Under 35 U.S.C.371, copy of unsigned Declaration for Patent Application, copy of Published Specification, International Search Report, Check No. 9151 in the amount \$1940 and Postal Receipt Card are being deposited with the United Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R.1.10 on the date indicated above and addressed to the Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: 15 September 2006



Melodi Dice

Novartis Vaccines and Diagnostics, Inc
4560 Horton Street
Emeryville, California 94608
United States of America